Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings (HRMY)
NASDAQ:HRMY
RESEARCH TOOLSreports
Holding HRMY?
Track your performance easily
Earnings Data
Report Date
Feb 19, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.68Last Year’s EPS
$0.45Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 29, 2024
|% Change Since: -4.11%
|Next Earnings Date:Feb 19, 2025
Earnings Call Sentiment|Positive
The earnings call presents a positive outlook with a strong financial performance, robust pipeline, and strategic plans for future growth. Despite increased operating expenses and some long timelines for clinical data, the company maintains a positive trajectory with significant market opportunities.Company Guidance
During Harmony Biosciences' Q3 2024 earnings call, the company reiterated its net revenue guidance for 2024, ranging from $700 million to $720 million, highlighting a strong quarter with $186 million in net revenue from WAKIX, which surpassed $2 billion in cumulative net sales since its launch. The company emphasized its robust pipeline, poised to deliver over $3 billion in future net revenue, with three orphan rare CNS franchises, each having peak sales potential of $1 billion to $2 billion. Harmony anticipates launching one or more new products or indications annually over the next five years, with near-term catalysts including the FDA's decision on their idiopathic hypersomnia sNDA and top-line data from the ZYN-002 trial in Fragile X syndrome. The company reported approximately $505 million in cash, cash equivalents, and investments as of September 30, underscoring its strong financial position to pursue additional business development opportunities.Robust Pipeline and Growth Potential
Harmony's late-stage pipeline is poised to deliver one or more new product or indication launches each year over the next 5 years. The pipeline includes 8 assets across 13 development programs, with 3 in pivotal Phase III trials. The company anticipates over $3 billion in net revenue driven by these developments.
Strong Financial Performance
Harmony reported net revenues of $186 million for Q3 2024, compared to $160.3 million in the prior year quarter, reflecting strong demand for WAKIX. The company has $505 million in cash and equivalents, allowing for strategic business development.
WAKIX Market Performance
WAKIX surpassed $2 billion in cumulative net sales since launch. Harmony reiterates 2024 net revenue guidance of $700 million to $720 million and is confident in WAKIX reaching $1 billion in sales for narcolepsy alone.
Idiopathic Hypersomnia sNDA Submission
Harmony is on track to submit an sNDA for pitolisant in idiopathic hypersomnia by year-end 2024, based on strong long-term extension study data showing efficacy.
---
HRMY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
HRMY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 29, 2024 | $35.75 | $41.49 | +16.06% |
| Aug 06, 2024 | $30.92 | $32.83 | +6.18% |
| Apr 30, 2024 | $29.25 | $30.91 | +5.68% |
| Feb 22, 2024 | $33.00 | $31.45 | -4.70% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Harmony Biosciences Holdings (HRMY) report earnings?
Harmony Biosciences Holdings (HRMY) is schdueled to report earning on Feb 19, 2025, TBA Not Confirmed.
What is Harmony Biosciences Holdings (HRMY) earnings time?
Harmony Biosciences Holdings (HRMY) earnings time is at Feb 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HRMY EPS forecast?
HRMY EPS forecast for the fiscal quarter 2024 (Q4) is $0.68.
---